Becton, Dickinson and Company announced a partnership with the U.S. government on Tuesday to drastically expand domestic manufacturing and fortify the supply chain for critical medical products. The company plans to invest $19 billion across the U.S. over several years, covering capital, operational, and supply chain enhancements, with $3 billion of that total channeled exclusively into expanding key manufacturing facilities nationwide. The expansion is expected to boost end-to-end U.S. production by roughly 5 billion essential medical consumables every year and lift the company's share of domestically sourced consumables to approximately 80%. Becton Dickinson also pledged to produce 100% of the needles it sells in America using solely American-made steel, and the agreement shields it from future Section 232 tariffs on specified products and materials as long as it meets agreed-upon operational milestones. Because officials have yet to determine the final product scope and tariff rates, the company has not quantified the financial impact but said it will provide updates when authorities finalize the actions.
Becton Dickinson and CompanyBecton Dickinson pledges $19B investment in U.S. manufacturing expansion, including $3B for facilities.
